psoriatic arthritis

AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi

https://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/

J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okay

https://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis

https://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/

J&J filing aims Tremfya at crowded psoriatic arthritis market

https://pharmaphorum.com/news/jj-filing-aims-tremfya-at-crowded-psoriatic-arthritis-market/

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

https://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

https://pharmaphorum.com/news/novartis-eric-hughes-cosentyx-secukinumab/

Novartis tests Cosentyx against Humira and biosimilars

https://pharmaphorum.com/news/novartis-tests-cosentyx-humira-biosimilars/

Pfizer’s Xeljanz approved in psoriatic arthritis

https://pharmaphorum.com/news/pfizers-xeljanz-approved-psoriatic-arthritis/

Celgene’s Otezla on course to become blockbuster

https://pharmaphorum.com/news/celgenes-otezla-course-become-blockbuster/

Close in 10 seconds

Pharmaphorum.com

Search